Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Genetic Markers in Choosing Pharmacological Treatment for Smoking Cessation With Bupropion and Varenicline and Its Implications for Combining Drugs: Randomized Control Study.

NCT03362099 is registered in ClinicalTrials.gov with University of Sao Paulo General Hospital as lead sponsor.

NCT NCT03362099
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03362099 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Genetic Markers in Choosing Pharmacological Treatment for Smoking Cessation With Bupropion and Varenicline and Its Implications for Combining Drugs: Randomized Control Study.
Lead sponsor
University of Sao Paulo General Hospital
Phase
Phase 4
Overall status
Completed
Start date
November 1, 2016
Completion date
April 15, 2022
Enrollment
361 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

genetic predisposition, smoking cessation